Antengene receives USD60m upfront payment from UCB

BioArctic's partner Eisai presents new clinical data on Leqembi subcutaneous autoinjector at AAIC 2026

FDA approves Sanofi's subcutaneous Sarclisa Escena as first anticancer therapy delivered via on-body injector

Nexstim expands Health Canada approval for NBS 6

Biohaven announces scientific leadership changes

DIA and MHRA plan global regulatory science summit in London

MetaVia completes DA-1726 dose titration in Phase 1 Part 3 study for obesity treatment

Ipsen reports positive Phase III results for Dysport in episodic and chronic migraine

Ionis and AstraZeneca's eplontersen Phase 3 ATTR-CM trial misses primary endpoint, subgroup analysis shows nominal benefit

Altruist Biologics' Hangzhou ADC facility approved for segmented production

Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma

Lynk Pharmaceuticals reports first patient dosed in Phase II clinical trial for vitiligo treatment

HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed

Keenova reports positive Phase 3 results for XIAFLEX in plantar fibromatosis

GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study